Pegaptanib sodium for the treatment of neovascular age-related macular degeneration

Author： Moshfeghi Andrew A   Puliafito Carmen A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.5, 2005-05, pp. : 671-682

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost Effectiveness of Pegaptanib for the Treatment of Age-Related Macular Degeneration in the UK

By Wolowacz Sorrel E.  

PharmacoEconomics, Vol. 25, Iss. 10, 2007-01 ,pp. : 863-879

Adis International

Access to resources Recommend Favorite

Pegaptanib: In Exudative Age-Related Macular Degeneration

By Siddiqui M. Asif A.   Keating Gillian M.  

Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. : 1571-1577

Adis International

Access to resources Recommend Favorite

Pegaptanib of value for age-related macular degeneration

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 542, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

VEGF inhibitors for the treatment of neovascular age-related macular degeneration

By Barakat Mark Rami   Kaiser PK  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 5, 2009-05 ,pp. : 637-646

Informa Healthcare

Access to resources Recommend Favorite

An update on the pharmacotherapy of neovascular age-related macular degeneration

By Freund K Bailey   Mrejen Sarah   Gallego-Pinazo Roberto  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1017-1028

Informa Healthcare

Access to resources Recommend Favorite